Erectile dysfunction (ED) affects an estimated 30 million men in the US, with prevalence increasing substantially after age 40. While PDE5 inhibitors (Viagra, Cialis) address vascular erectile mechanics effectively, they leave several ED presentations undertreated: psychogenic ED where desire is absent, vascular ED with significant endothelial dysfunction, and cases where PDE5 inhibitors fail or are contraindicated. Research peptides — particularly PT-141 and BPC-157 — offer mechanistically distinct approaches to each of these presentations.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
BPC-157's vascular and nerve repair effects represent actual tissue-level changes rather than temporary pharmacological effects, so improvements may persist beyond the cycle. However, the evidence for this specifically in human ED is animal-based and extrapolated. Regular cycling is common in practice.
PT-141: Addressing Psychogenic and Desire-Deficit ED
PT-141 (bremelanotide) is the most directly relevant peptide for erectile dysfunction, having been studied specifically in men with ED in Phase II trials before Palatin Technologies pivoted to the female HSDD indication for FDA approval. The male Phase II data showed significant improvement in erectile function scores and successful penetration rates in men with psychogenic ED and mixed ED where PDE5 inhibitors provided incomplete response.
PT-141's central melanocortin mechanism addresses the desire/arousal initiation phase that PDE5 inhibitors cannot generate. In men whose ED is primarily psychogenic (performance anxiety, stress-related, low libido-related), where the vascular pathway is functional but the central arousal signal is insufficient, PT-141 provides a mechanism unavailable from conventional ED medications. Typical dosing is 1–2 mg subcutaneously 45–90 minutes before activity.
BPC-157: Vascular and Neurological Repair
BPC-157's relevance for ED operates through two pathways: vascular repair and neurological recovery. Animal studies show BPC-157 significantly upregulates VEGFR2 (vascular endothelial growth factor receptor 2) and promotes angiogenesis — the formation of new blood vessels. Since vasculogenic ED is fundamentally an endothelial/vascular disease (ED often precedes major cardiovascular events as a sentinel symptom), BPC-157's vascular repair properties are mechanistically relevant.
Additionally, BPC-157 has shown nerve repair effects in animal models, relevant for post-surgical ED (particularly post-prostate surgery where cavernous nerve damage is the primary mechanism) and diabetic neuropathy-associated ED. These are longer-latency effects than PT-141's acute action — BPC-157 for vascular/neurological ED should be understood as a chronic repair intervention rather than an acute performance aid. Typical dosing: 250–500 mcg/day subcutaneously for 6–12 week cycles.
Melanotan II: Erection Without Arousal (and Its Limitations)
Melanotan II (MT-II) acts on melanocortin receptors similarly to PT-141 but with broader receptor targeting (MC1R–MC5R vs PT-141's relative selectivity for MC3R/MC4R). MT-II produces spontaneous erections in animal models and humans — literally generating mechanical erections in the absence of sexual stimulation in some users. This spontaneous erection effect is considered a side effect in MT-II's primary (tanning) use case, but highlights its potent melanocortin agonism on erectile tissue.
MT-II is not FDA-approved (unlike PT-141), has a less studied safety profile, and the spontaneous erection effect can be uncomfortable or socially problematic. As an ED treatment it is used less frequently than PT-141 given the latter's better-characterised safety profile and more selective receptor action. Those already using MT-II for tanning purposes often note the incidental erectile benefit; as a primary ED treatment, PT-141 is generally preferred.
Stacking for Complex ED
ED with multiple contributing factors (vascular damage + reduced desire + psychological component) may benefit from combining approaches. A research protocol for complex ED might include: BPC-157 chronically for vascular and neurological repair (250 mcg/day), PT-141 acutely as-needed for arousal initiation, and a PDE5 inhibitor for vascular mechanics on use days. This multi-mechanism approach addresses the condition more comprehensively than any single agent.
Additionally, testosterone optimisation should be investigated before or alongside peptide use — hypogonadism is a common, undertreated contributor to ED that peptides do not address. A full hormonal panel is appropriate as a baseline before assuming peptide intervention is the primary lever.
How Does Peptides for Work?
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| PT-141 | 1–2 mg | SubQ | Acute (as-needed) | Psychogenic / desire-deficit ED |
| BPC-157 | 250–500 mcg | SubQ | Daily, 6–12 weeks | Vascular / neurological repair |
| Melanotan II | 0.25–0.5 mg | SubQ | Acute / cycling | Melanocortin agonism — less selective |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Peptides are not direct replacements for PDE5 inhibitors — they work through different mechanisms for different ED subtypes. PT-141 addresses psychogenic and desire-deficit ED where PDE5 inhibitors are insufficient; BPC-157 addresses vascular repair as a long-term intervention. Men with straightforward vasculogenic ED who respond well to PDE5 inhibitors generally have no reason to substitute them with peptides. The best use case for peptides in ED is as additions to a treatment regimen or alternatives when PDE5 inhibitors are ineffective or contraindicated.
PT-141 typically takes 45–90 minutes to produce noticeable arousal-enhancing effects. Planning accordingly — administering 1–1.5 hours before anticipated activity — provides optimal timing. Effects can persist for 6–12 hours.
BPC-157's vascular and nerve repair effects represent actual tissue-level changes rather than temporary pharmacological effects, so improvements may persist beyond the cycle. However, the evidence for this specifically in human ED is animal-based and extrapolated. Regular cycling is common in practice. Results depend heavily on the underlying cause of the ED — vascular or neuropathic presentations have the strongest mechanistic rationale.
Diabetic ED has both vascular (endothelial dysfunction, reduced nitric oxide bioavailability) and neurological (autonomic neuropathy) components. BPC-157's angiogenic and nerve repair properties address both mechanisms, making it mechanistically relevant for diabetic ED. PT-141 addresses the central arousal component but does not repair the peripheral vascular or neurological damage that drives diabetic ED mechanically.